ASCO 2024: What are some of the latest advancements in cancer trials?
This issue of our newsletter is supported by Inpart.
ASCO 2024 was held in Chicago where experts gathered to showcase promising cancer research.
Pharma giants like AbbVie and AstraZeneca as well as biotechs like Biomica, Alligator Bioscience, and Nanobiotix, presented encouraging data for their drug candidates.
Cancer vaccines were also part of the discussion, including Moderna’s mRNA technology and Elicio Therapeutics’ early-stage off-the-shelf vaccine.
Labiotech spoke to Ketan Patel, from Clarivate, to discuss the clinical trends discussed at ASCO 2024.
To find out more, read the full article: “ASCO 2024: The latest advances in oncology clinical trials”
A MESSAGE FROM OUR SPONSOR INPART
Accelerating innovation with J&J
Watch the replay of our recent webinar with J&J, to learn about how they were ranked 1st amongst top pharma companies for overall partnering experience in our Partnering 2030 survey.
Catch up on our conversation with VP Early Innovation Partnering Ajay Gautam to learn how collaboration with biotech companies powers J&J’s innovation strategy.
Recommended by LinkedIn
🔥 More noteworthy articles from this week:
Small interfering RNA (siRNA) carry great promise in the biotechnology industry. It is an essential component of the RNA interference pathway, and has the potential to treat a wide range of diseases, from genetic disorders and cancers to viral infections. In this article, we take a look at eight companies contributing to the field of siRNA.
Pharma giant Pfizer’s Tivdak was approved by U.S. regulators for the treatment of cervical cancer last month. As current standards of care include surgery, radiation, and chemotherapy, new drugs broaden treatment options, and extend to more patient groups.
A CRISPR clinical trial recently had encouraging results in treating patients with a rare form of blindness. Rigorous research in the field, which has been going on for more than a decade now, might just pay off, as scientists believe that the technology could treat inherited blindness.
As the biotech industry in France has been gaining momentum in recent years, there are now many universities in the country, several of which are based in the biotech hub of Paris. In this article, we take a look at five universities offering a Masters in biotechnology in France.
Finland’s biotech industry is dynamic and mainly involved in areas such as precision medicine and immunotherapy. While Finland’s biotech isn’t solely focused on health, and contributes to the fields of food and sustainability, healthcare remains a strong component of the country’s landscape. In this article, we take a look at seven biotechs pushing the industry forward in Finland.
With single-gene based drug target identification methods getting saturated, the scientific world is venturing beyond traditional approaches to enhance early drug discovery. We explore how combining multi-disciplinary cutting-edge tools like multivariate analysis can help identify multi-gene targets and improve patient outcomes through precision medicine.
Leukodystrophies are a group of rare genetic disorders for which there is currently no curative therapy. In conversation with Synaptix Bio CEO Dan Williams, we discuss novel treatments for rare pediatric diseases, and how the company aims to treat leukodystrophies.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.